Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells

Interleukin-2 (IL-2) is a T-cell proliferating factor used for cancer immunotherapy. Here, the authors develop a long-lived variant of IL-2 that, mutated in its binding domain, drives a much more potent tumour regression by depleting CD25+ CD4+regulatory T-cells via targeting them for phagocytosis.

Bibliographic Details
Main Authors:	Rodrigo Vazquez-Lombardi, Claudia Loetsch, Daniela Zinkl, Jennifer Jackson, Peter Schofield, Elissa K. Deenick, Cecile King, Tri Giang Phan, Kylie E. Webster, Jonathan Sprent, Daniel Christ
Format:	Article
Language:	English
Published:	Nature Publishing Group 2017-05-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/ncomms15373

id	doaj-5b8e946c736b4be78cfb86f8d067ec42
record_format	Article
spelling	doaj-5b8e946c736b4be78cfb86f8d067ec422021-05-11T07:45:43ZengNature Publishing GroupNature Communications2041-17232017-05-018111210.1038/ncomms15373Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cellsRodrigo Vazquez-Lombardi0Claudia Loetsch1Daniela Zinkl2Jennifer Jackson3Peter Schofield4Elissa K. Deenick5Cecile King6Tri Giang Phan7Kylie E. Webster8Jonathan Sprent9Daniel Christ10Immunology Division, Garvan Institute of Medical ResearchImmunology Division, Garvan Institute of Medical ResearchImmunology Division, Garvan Institute of Medical ResearchImmunology Division, Garvan Institute of Medical ResearchImmunology Division, Garvan Institute of Medical ResearchImmunology Division, Garvan Institute of Medical ResearchImmunology Division, Garvan Institute of Medical ResearchImmunology Division, Garvan Institute of Medical ResearchImmunology Division, Garvan Institute of Medical ResearchImmunology Division, Garvan Institute of Medical ResearchImmunology Division, Garvan Institute of Medical ResearchInterleukin-2 (IL-2) is a T-cell proliferating factor used for cancer immunotherapy. Here, the authors develop a long-lived variant of IL-2 that, mutated in its binding domain, drives a much more potent tumour regression by depleting CD25+ CD4+regulatory T-cells via targeting them for phagocytosis.https://doi.org/10.1038/ncomms15373
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Rodrigo Vazquez-Lombardi Claudia Loetsch Daniela Zinkl Jennifer Jackson Peter Schofield Elissa K. Deenick Cecile King Tri Giang Phan Kylie E. Webster Jonathan Sprent Daniel Christ
spellingShingle	Rodrigo Vazquez-Lombardi Claudia Loetsch Daniela Zinkl Jennifer Jackson Peter Schofield Elissa K. Deenick Cecile King Tri Giang Phan Kylie E. Webster Jonathan Sprent Daniel Christ Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells Nature Communications
author_facet	Rodrigo Vazquez-Lombardi Claudia Loetsch Daniela Zinkl Jennifer Jackson Peter Schofield Elissa K. Deenick Cecile King Tri Giang Phan Kylie E. Webster Jonathan Sprent Daniel Christ
author_sort	Rodrigo Vazquez-Lombardi
title	Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
title_short	Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
title_full	Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
title_fullStr	Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
title_full_unstemmed	Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
title_sort	potent antitumour activity of interleukin-2-fc fusion proteins requires fc-mediated depletion of regulatory t-cells
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2017-05-01
description	Interleukin-2 (IL-2) is a T-cell proliferating factor used for cancer immunotherapy. Here, the authors develop a long-lived variant of IL-2 that, mutated in its binding domain, drives a much more potent tumour regression by depleting CD25+ CD4+regulatory T-cells via targeting them for phagocytosis.
url	https://doi.org/10.1038/ncomms15373
work_keys_str_mv	AT rodrigovazquezlombardi potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT claudialoetsch potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT danielazinkl potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT jenniferjackson potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT peterschofield potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT elissakdeenick potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT cecileking potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT trigiangphan potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT kylieewebster potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT jonathansprent potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT danielchrist potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells
_version_	1721451630858076160

Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells

Similar Items